Proarrhythmia

Proarrhythmia represents the unexpected exacerbation or emergence of new arrhythmias subsequent to antiarrhythmic therapy. It stands as a significant clinical concern as these medications, designed to control or prevent heart arrhythmias, can paradoxically cause or aggravate them.

Introduction

While antiarrhythmic drugs are formulated to treat abnormal heart rhythms, they can occasionally lead to the advent of new or more frequent arrhythmic events, hence the term 'proarrhythmia'. This phenomenon isn't solely confined to antiarrhythmic medications; drugs for various other indications can also manifest this side effect.

Classification and Types

Categorized largely based on the Vaughan Williams classification (VW) for antiarrhythmic drugs, the principal types of Proarrhythmia that can be observed during treatment for conditions like Atrial Fibrillation or Atrial Flutter include:

Ventricular Proarrhythmia

• Torsades de pointes: Commonly associated with VW type IA and type III drugs.
• Sustained monomorphic ventricular tachycardia: Typically observed with VW type IC drugs.
• Sustained polymorphic ventricular tachycardia/ventricular fibrillation without long QT: May be caused by VW types IA, IC, and III drugs.

Atrial Proarrhythmia

• Conversion from atrial fibrillation to flutter, which may sometimes be a sought-after effect, especially with VW type IC drugs or amiodarone.
• An elevation in the defibrillation threshold: This is a potential concern with VW type IC drugs.
• Provocation of recurrence, though it remains a rarity, can be seen with VW types IA, IC, and III drugs.

Abnormalities of Conduction or Impulse Formation

• Issues like sinus node dysfunction and atrioventricular block can arise from almost all drugs.
• Enhanced conduction over an accessory pathway can be induced by drugs like digoxin, intravenous verapamil, or diltiazem.
• Acceleration of ventricular rate during atrial fibrillation is sometimes observed with VW type IA and type IC drugs.

Risk Factors

Certain individuals and conditions predispose a heightened susceptibility to proarrhythmia:

• Structural heart diseases, especially when linked with LV systolic dysfunction.
• Utilization of Class IC agents.
• Increased age.
• Female gender.

Clinical Considerations

For an optimal therapeutic outcome and minimization of proarrhythmia risk, certain clinical pointers aligned with drug classes are valuable:

• Class IA drugs: Manifestations tend to be dose-independent, surfacing even at standard levels. Regular monitoring of the QT interval is pivotal.
• Class IC drugs: Proarrhythmia can sometimes be provoked by an escalated heart rate. Post-loading exercise stress tests are advisable.
• Class III drugs: These are dose-dependent effects. Close vigilance on parameters like bradycardia and prolonged QT is essential.

Preclinical Testing and Drug Development

The failure of novel drugs due to undetected arrhythmogenic properties, especially during the advanced phases of development, inflicts significant financial burdens. It's also a primary reason for subsequent drug withdrawals from the market. Given these challenges:

• The FDA now necessitates testing all new drugs for possible arrhythmogenic properties, fostering a demand for precise yet economical preclinical screening tools.
• Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) present a promising approach, albeit with maturity limitations. Optimizing these cell constructs to closely emulate adult myocardial tissue is paramount for reliable and effective preclinical screening.

Proarrhythmia Resources
Latest articles Most recent articles Ongoing trials	Wikipedia